Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Shares Are Jumping Today

By Keith Speights – Jun 15, 2020 at 10:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors liked the biotech's $200 million capital raise.

What happened

Shares of Novavax (NVAX -6.42%) were jumping 8.6% higher as of 11:22 a.m. EDT on Monday after rising as much as 12.6% earlier in the day. The nice gain resulted from the company's announcement that it was raising around $200 million in gross proceeds through a private placement deal with RA Capital Management. Novavax will sell Series A Convertible preferred stock that's convertible into nearly 4.4 million shares of common stock to an affiliate of RA Capital.

So what

Novavax's latest capital raise underscores just how attractive the company has become to the investment manager community. CEO Stanley Erck said that the biotech's management team believes the support from RA Capital "signals a high level of confidence in the significant progress of our COVID-19 and influenza vaccine programs." He's right. And it's not just investment managers who are interested in Novavax.

Gloved hand holding COVID-19 vaccine syringe

Image source: Getty Images.

In May, the company picked up the biggest funding to date from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop and manufacture a COVID-19 vaccine. CEPI agreed to provide up to $384 million in additional funding on top of an initial $4 million investment. Earlier this month, Novavax won a $60 million contract with the U.S. Department of Defense to deliver 10 million doses of its COVID-19 vaccine, NVX‑CoV2373. 

While there's a high level of interest in Novavax's COVID-19 vaccine program, the company has another promising candidate with its flu vaccine NanoFlu. Novavax reported positive late-stage results for NanoFlu in March. The $200 million raised through this latest private placement deal will help fund both continued development of NVX‑CoV2373 and the regulatory approval process for NanoFlu.

Now what

There are two different fronts for investors to watch with Novavax now, both of which could serve as major catalysts for the biotech stock. Novavax expects to report preliminary results in July from its phase 1 clinical study evaluating the COVID-19 vaccine candidate. It's also moving toward filing for U.S. regulatory approval of NanoFlu.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$21.00 (-6.42%) $-1.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.